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INTRODUCTION 
Pregnancy induced hypertension  commonly affects  10-
15 %  of  pregnant women.So the constant endeavour for 
obstetricians to identify the risk  factors and its 
complications.So it is important to predict the preeclampsia 
then prevention will follow routinely.Abnormal  placentation 
with impaired trophoblastic invasion is the initiating 
factor
18
.In the mid trimester due to the immunological 
changes in the trophoblasts cause secretory response leads to 
rise in beta HCG levels. 
In the first trimester there is a drop in blood pressure 
because of  the active vasodilatation,and the normal 
physiological change in blood pressure during pregnancy is 
mediated  through the action of local mediators like 
prostacyclin and nitric oxide.The fall in blood pressure 
primarily affects the diastolic pressure and reduction of 10 
mm Hg is usual by 13–20 weeks gestation. Blood pressure 
continues to drop until 22–24 weeks till the nadir level then 
there is a gradual rise in blood pressure until term when pre-
pregnancy levels are attained.Soon after delivery, blood 
pressure usually drops then rises over the first five days of 
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postnatal period.Even women whose blood pressure was 
normal throughout pregnancy may have transient rise in blood 
pressure in the early post partum period because of the 
vasomotor instability. 
HYPERTENSION IN PREGNANCY  
It is diagnosed by an absolute rise in blood pressure or 
from a relative rise above the blood pressure at the time of 
booking. The convention for the absolute value is a systolic 
blood pressure 140 mm Hg or a diastolic blood pressure 90 
mm Hg. However it should be accepted that blood pressure is 
gestation related. A diastolic blood pressure of 90 mm Hg is 3 
standard deviations above the mean for mid pregnancy, 2 SD 
at 34 weeks, and 1.5 SD at term. 
The relative increase in blood pressure point out that a 
increase in systolic pressure of 30 mm Hg or increase in 
diastolic pressure of 15 mm Hg above blood pressure at the 
time of initial examination. Blood pressure must be increased 
on at least two occasions and the blood pressure should be 
taken with the woman seated measured 6 hours gap with the 
proper cuff size. Late in the second trimester and in the third 
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trimester, venous return may be blocked by the enlarged 
uterus and for the supine position blood pressure should be 
measured with the woman in left lateral side
15
. 
Preeclampsia complications affect about 4-5%of 
pregnancies, and other hypertensive disease present about 8-
10 % of pregnancies. Hypertensive disorders in pregnancy 
leads on to higher rates of perinatal mortality, and severe 
morbidity mainly in patients with severe preeclampsia, 
eclampsia,  haemolysis, increased  liver function test and low 
platelet count. 
Preeclampsia is a pregnancy specific hypertensive 
disorder related with significant perinatal mortality and 
morbidity.With the increasing kind of the disease process 
many complications  as well as the perinatal mortality  have 
declined over the past few years. In the developing countries, 
the rates of mortality and morbidity stil l  at  a higher level 
.Hence diagnosis of the disease process at correct time helps 
to prevent the disease progression and its mortality. Since 
prevention is better than cure, the prediction of PIH at earlier 
pregnancy period helps to prevent the progression of 
preeclampsia and its morbidity and mortality.  
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Prevention of disease has three aspects and primary 
prevention by avoiding the occurrence of a disease, secondary 
prevention by breaking of the disease process before 
emergence of obvious clinical disease and tertiary prevention 
by avoidance of complications caused by disease process and 
is almost similar to the treatment.  
PRIMARY PREVENTION                                                          
Primary prevention is by the modification of risk 
factors and  identifying underlying medical diseases like 
chronic hypertension, diabetes, renal disease, obesity 
(BMI>35kg/m
2
),maternal low birth weight, polycystic ovarian 
syndrome, migraine, collagen vascular diseases, uncontrolled  
hyperthyroidism, factor V leiden deficiency, activated 
proteinC defiency  and antiphospholipid antibodies. Although 
it is recommended to modify the risk factors for preeclampsia 
it would be possible only in a small number of cases.  
But the relative risk of preeclampsia in high risk 
situations as suggested by Duckitt and Harrington, the early 
diagnosis of preeclampsia with timely referral for the higher 
institute care using PRECOG guidelines will help in their 
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appropriate management and prevent them going to severe 
preeclampsia and its complications. 
SECONDARY PREVENTION 
Secondary prevention of a disease is possible only  
When the accurate knowledge of pathogenesis and 
genetics available,  
Availability of  method for early identification and 
means of intervention and modification of the 
pathophysiology of disease process. 
Hence screening methods with criteria including proper 
history taking , examination and laboratory values have been 
used as the methods of secondary prevention of the 
preeclampsia. 
Abnormal placentaion with the impaired trophoblastic 
invasion is the initiating factor for preeclampsia. During mid 
trimester of pregnancy the immunological changes in the 
trophoblasts and secretory response leads to a rise in beta 
HCG levels. 
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In the second trimester of pregnancy serum beta HCG 
levels helps to predict pregnancy induced hypertension and 
hence prevention will follow routinely. Serum Beta HCG 
levels are measured from gestational age 13 to 20 weeks and 
they are followed till term and postnatal for prediction of 
pregnancy induced hypertension and its complications.  
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AIM AND OBJECTIVE 
1) To predict the pregnancy induced hypertension by 
elevated Beta HCG levels in the second trimester of 
pregnancy. 
2) To  assess the severity of PIH correlated with the 
elevated levels of Beta HCG. 
3) Secondary outcome to study the prediction of PIH 
based on the parameters like Age, Parity, Gestational 
Age ,Body Mass Index and the Past History of PIH. 
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REVIEW OF LITERATURE 
HYPERTENSIVE DISORDERS IN PREGNANCY  
1) Chronic hypertension 
2) Gestational hypertension 
3) Preeclampsia  
4) Preeclampsia superimposed on chronic hypertension 
CHRONIC HYPERTENSION 
It affects 3–5% of pregnancies, incidence being higher 
in 30-40yrs of age. It is diagnosed by with the past history of 
hypertension in pre pregnancy period or an increased blood 
pressure > 140/90 mm Hg before 20 weeks gestation and the 
occurrence of hypertension before pregnancy.  
GESTATIONAL  HYPERTENSION 
Hypertension occurring after 20 weeks of gestational 
period in the previously normal woman  without significant 
proteinuria or other features of preeclampsia  is known as 
gestational or pregnancy induced hypertension. It occurs in 
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6–7% of pregnancies and disappears by 6 weeks of 
postpartum period. The risk of superimposed preeclampsia is 
15–25%  but this risk is depends upon the gestational period 
at which the hypertension  develops. But the risk falls to10% 
when gestational hypertension is diagnosed in the third 
trimester of pregnancy. 
PREECLAMPSIA 
Preeclampsia usually occurs after 20 weeks gestation 
and it is a multi organ involvement disorder. It consists of 
triad of hypertension, oedema, and proteinuria, also it 
includes  an gestational elevation of blood pressure together 
with 0.3 g/dl proteinuria per 24 hours. Nowadays oedema is 
not included  in the criteria for the diagnosis 
PATHOGENESIS 
Abnormal placentation  
 In the first trimester of healthy pregnancy the 
trophoblast  normally invades the uterine decidua layer the 
inner layer of the myometrium. The interstitial trophoblast 
surrounds the arteries and endovascular trophoblast 
penetrates the spiral artery lumen
19
.This migration will 
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convert the small calibre muscular arteries into large 
capacitance low resistance vessels in  the intervillous space
23
. 
Development of uteroplacental vessels proceeds in two 
stages : 
1) Before 12 weeks post fertilisation upto the interface 
between decidua and myometrium  
2) Between 12-16 weeks and involves invasion of intra 
myometrial segments of spiral arteries  
These changes starts occurring  in the first trimester and 
completed in the second trimester of pregnancy when another 
wave of trophoblast migration alters the myometrial segments 
of the arteries. 
In preeclampsia these vascular alterations do not occur 
or they are limited to vessels in the decidua. In addition 
trophoblastic invasion is incomplete, shallow and it’s deeper  
myometrial arterioles do not lose their endometrial lining and 
musculo elastic tissue . 
The secondary stage of preeclampsia involves the 
endothelial dysfunction and vasospasm .Endothelial 
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dysfunction is a central feature in preeclampsia resulting in 
vascular reactivity ,activation of coagulation cascade and loss 
of vascular integrity.Biochemical markers of endothelial 
dysfunction such as plasma fibronectin and thrombomodulin 
are elevated in   preeclamptic  patients. 
Several angiogenenic and anti angiogenenic substances 
are involved in the placental vascular development 
,imbalance in circulating  proangiogenic (VEGF,PGF) and 
antiangiogeneic factors contribute to pathogenesis.  
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RISK FACTORS FOR PREECLAMPSIA
21 
 Parity 
 Age>35 years  
 History of preeclampsia in previous pregnancy 
 Pre-existing medical disorders  
o Hypertension  
o Diabetes mellitus  
o Obesity  
o Renal disease 
o Vascular disease 
o Autoimmune disease 
  Low socioeconomic status 
o Obstetric factors  
o Multiple gestation 
o Hydatidiform mole 
o Hydrops foetalis 
 13 
o Abnormal uterine artery Doppler at 18-24 weeks 
  Interval from last pregnancy >10 years  
SIGNS AND SYMPTOMS 
 Headache ,visual disturbances 
 Epigastric or right upper quadrant pain  
 Oliguria  <500ml urine in 24 hours  
 Thrombocytopenia 
 Significant protenuria  >5g/24 hour 
 Convulsions (cerebral oedema) 
LABORATORY TESTS IN PREECLAMPSIA 
 Urinalysis >1+on dipstick,  
24 hours urinary protein for quantification of 
proteinuria 
 Complete blood count – Thrombocytopenia  
<1,00,000cells /mm
3
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 Renal parameters:  elevated serum creatinine  
>1.2mg/dl associated with reduced creatinine clearance  
and ‘‘normal’’ values  indicate renal impairment.  
 Liver function tests - Increase  transaminase 
concentrations  and increase  LDH  >800IU/L 
 Serum Uric acid - Like blood urea this value is also 
lower in normal pregnancy due to increased clearance 
,it is raised in preeclampsia resulting in hyperuricaemia 
 Coagulation studies -platelet count, prothrombin time, 
partial thromboplastin time, fibrin degradation products 
and fibrinogen levels to  exclude disseminated 
intravascular coagulation 
 Plasma and urinary metanephrines , serum renin and 
aldosterone levels to exclude other causes of 
hypertension 
COUNSELLING  
Nearly half of pregnancies are unplanned and hence pre 
pregnancy counselling is not possible for all patients. Women 
with chronic hypertension  should be assessed before 
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pregnancy. Hence exclusion of the secondary causes of 
hypertension like vascular ,renal and endocrine causes and 
the control of hypertension before pregnancy  explain the 
patients regarding the risk of  preeclampsia superimposed  
and alteration of drugs taken before  and their need to change 
during first trimester, continuing till term and to continue in 
the postpartum. 
General maternal care, blood pressure measurement and 
the search for proteinuria forms the basis of antenatal 
screening of all pregnant women for preeclampsia. If ‘‘white 
coat’’ hypertension is suspected, ambulatory monitoring will 
be helpful  as in the non-pregnant population. Women who 
have been defined as at increased risk of preeclampsia are 
monitor more closely, often in a specialised obstetric clinic. 
Early risk assessment involves Doppler ultrasound evaluation 
of the uterine arteries around the time of the foetal anomaly 
scan at 20–22 weeks.  
Increasing blood pressure, deranged blood results, and 
the development of significant proteinuria  require enhanced 
surveillance. Greater than 1+ proteinuria on dip stick needs to 
be quantify with a 24 hour urine collection or 
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protein:creatinine ratio. The onset of significant proteinuria  
in the presence of renal disease  is among the best indicators 
of superimposed  preeclampsia. According to the maternal 
symptoms and clinical result and the growth nature of foetus  
a woman can be referred to a day appraisal unit for the 
routine outpatient assessment. 
Doppler evaluation of uterine arteries, Pulsed wave 
analysis and colour flow Doppler ultrasound assessment of 
the uterine arteries can divulge the augmented placental 
vascular resistance which result from complete or partial 
failure of trophoblast invasion of the spiral arteries. 
Besides to the amount of the resistance index, the 
presence of an abnormal uterine artery waveform also 
identified. Uterine artery Doppler is presented to high risk 
women at between 20–24 weeks of pregnancy and has useful 
prognostic control. For the woman with normal uterine 
Doppler evaluation at 20–24 weeks consider as low risk, 
whereas those with abnormal Doppler have about a 20% risk 
of developing preeclampsia and needs more attention. 
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DOPPLER STUDY OF UTERINE ARTERY 
 
Normal Uterine Artery Doppler flow form showing low 
resistance, high velocity wave form indicating low risk 
pregnancy. It is usually done at 16-20 weeks of pregnancy.  
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DOPPLER STUDY OF UTERINE ARTERY 
 
Abnormal flow velocity wave form with early diastolic 
notch indicates superimposed preeclampsia devel oping in 
women with chronic hypertension. It has high resistance and 
low velocity wave form.  
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 Foetal surveillance 
 Women with both chronic hypertension and 
preeclampsia are at danger of IUGR. Such women are 
monitored  by regular foetal ultrasound scans to 
measure the foetal growth, liquor volume, and umbilical 
artery blood flow. When preeclampsia is severe and 
there is important risk of delivery before 34 weeks 
gestation, intramuscular steroids like dexamethasone or 
betamethasone  are given to the mother to improve 
foetal outcome.  
Over many years different laboratory tests that has been 
used  for the prediction of preeclampsia .These tests are  used 
as predictors when preeclampsia occurs in a full fledged 
form. Thus this explains the fact why screening in the first 
trimester is unlikely to make results as in the second 
trimester. The present use of several markers in the screening 
process reflects that various  aspects of the disease processes  
thus increasing sensitivity and specificity of the disease 
.Finally  the screening tests used to predict needs  to be 
simple, fast and cost effective. Several angiogenic factors 
,antiangiogeneic  factors and proteomics studies are used as 
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promising predictors that can be used in the future .Hence 
these promising tests are not used routinely since due to its 
high cost.  
 Preeclampsia is one of types of hypertension in 
pregnancy that occurs in 4-8% of all pregnancies.  
 Preeclampsia/eclampsia  complex  is responsible for 
nearly half of the maternal deaths in India. Infants born 
to women of preeclampsia have an increased risk of 
complications compared to other pregnant women. Most 
dreaded and avoidable complication of infants of 
preeclampsia is prematurity due to premature 
termination of pregnancy. About 15% of preeclampsia 
occurs in early pregnancy before foetal maturity and 
hence preterm births occur only in about 15%  of  all  
pregnancies . 
 Clinical history, examination findings ,laboratory tests 
and other tests 
have been used to predict preeclampsia .In order to 
predict  the disease early  in first trimester and early second 
trimester seems sensible related to the impaired  
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uteroplacental tissue adaptation  that is responsible for 
established manifestation  of the disease process. 
Numerous clinical,biochemical and biophysical tests in 
early or mid pregnancy have been proposed for the prediction 
of preeclampsia 
These predictive tests related to placental perfusion and 
vascular resistance. 
Mean second trimester BP, intravenous infusion of  
Angiotensin 2,  roll over test , 24 hour ambulatory BP 
monitoring. 
Foetoplacental Endocrinology 
Alpha fetoprotein, Human Chorionic Gonadotrophin 
Renal function  
Serum Uric Acid or Microalbuminuria 
Endothelial function and endothelial platelet interaction 
Platelet Count, Anti Phospholipid  Antibodies, or 
Homocysteine. 
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Placental Hormones 
Activin, Inhibin A, Corticotrophin  Releasing Hormone 
(CRH) 
Angiogenic factors  
Vascular endothelial growth factor (VEGF), Placental 
growth factor (PGF) and Antiangiogeneic factors like soluble 
fms like tyrosine kinase 1 and soluble endoglin levels.   
 At present the link between angiogenic factors 
(placental growth factor vascular endothelial growth 
factor ) and antiangiogenic  factors  found be 
promising.  However endoglin (sEng) acting in concert 
with sFlt-1 could improve the prognostic performance. 
Alterations in placental proteins were considered using 
MALDI-TOF MS/MS proteomics study and revealed 
that there was over demonstration of chaperones 60 , 
ERp29, Cathepsin C, VDAC,  and Cathepsin  D in 
preeclampsia.  
Angiotensin Sensitivity Test 
Normally a pregnant woman displays reduced 
responsiveness to effects of  angiotensin 2 , in patients with 
 23 
preeclampsia plasma renin activity and angiotensin 2 levels 
are lower than normal throughout pregnancy .Only in the 
third trimester does the aldosterone level increase in 
hypertensive pregnancy. 
In addition the refractoriness to Angiotensin 2 is lost as 
early as the early second trimester , several weeks before the 
onset of hypertension ,in women who are destined to develop 
preeclampsia later in gestation. A greater presser response to 
infused angiotensin 2 has been demonstrated as early as 18-22 
weeks of gestation in normotensive who subsequently 
develop hypertension.  
This increased sensitivity to angiotensin 2 is the result 
of loss of vessel refractoriness is because of the down 
regulation of angiotensin  receptors in the presence of 
persistently its elevated level.  
Over past two decades, various studies reported that 
preeclamptic women showed an elevated presser response to 
vasopressin. The low sensitivity of these tests have raised the 
doubt of using angiotensin sensitivity as a predictor of 
preeclampsia. 
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 Renal Laboratory Tests 
Establishing abnormal levels of urine protein and urine 
albumin as sole predictor has not been established. The 24 
hours urinary  quantitative specimen >300mg /24 hours have 
been established and determination of urinary protein or 
albumin :creatinine ratio may supplant the 24 hour urinary 
protein.  
Random urine protein:creatinine ratio below 130 to 150 
mg/g -0.13 to 0.15 –indicate the likelihood of proteinuria 
exceeding 300mg/day is low and mid ranges that is 300mg /g 
-0.3-have poor sensitivity and specificity.  
Uric acid, Creatinine and Urine Microprotein, Calcium levels 
Renal blood flow and glomerular filtration are reduced 
in preeclampsia. Since renal blood flow and glomerular 
filtration are normally increased during pregnancy , levels 
usually reach the normal non pregnant values and very low 
levels are the consequence of reduction in GFR and the 
plasma uric acid concentration is typically elevated.  
High serum uric acid levels  > 6.5 g/dl were associated 
with  severity of preeclampsia. Hyperuricaemia  an early sign 
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of renal involvement in preeclampsia, is due to enhanced 
tubular reabsorption and increased placental urate production 
compensatory to increased oxidative stress. Urine sodium 
concentration is elevated in most preeclamptic patients and 
urine osmolality ,urine :plasma creatinine ratio and fractional 
excretion of sodium is indicative of pre renal involvement of 
the disease process. 
 Urinary proteomics 
Proteomic fingerprint associated with serpina and 
albumin fragments predicts preeclampsia with the accuracy 
and it also differentiates preeclampsia with other types of 
hypertensive disorders.  
Urinary Inhibin A 
Urinary Inhibin value is greatly increased in patients 
with preeclampsia,values more than 90pg/mg is associated 
with greater risk of developing preeclampsia. Cut off value 
for development of preeclampsia is 45pg/mg and values 
above this have a predisposition for development of 
preeclampsia. 
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Urinary Kallilrein Creatinine Ratio(Uk:Cr) 
Urinary kallikrein to creatinine ratio is measured and is 
a useful test for the predicting  preeclampsia later in 
pregnancy  and it is usually done between 16-20 weeks of 
gestation. This test has a better sensitivity and specificity 
compared to other renal parameters. 
Clinical value of Microtransferrunia and Microalbuminuria  
A number of investigators have evaluvated the potential 
value of micro albuminuria as a predictive test for 
preeclampsia. 
As reviewed by Conde Agudelo sensitivity was ranging 
between 7 to 90 percent,and specificity 29 and 97 percent  
and a recent study has shown that unacceptable sensitivity 
and specificity for urine albumin:creatinine  ratio.  
Urinary microalbuminuria and micro transferrinuria 
both has a better sensitivity and specificity than other 
parameters. Microtranferrinuria is potentially used as a better  
predictor of preeclampsia than micro albuminuria level. 
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Urinary excretion of N-acetyl-beta-glucosaminidine  
Urinary excretion of N acetyl beta glucosaminidase is 
increased in patients with preeclampsia and in normal 
pregnant woman than non pregnant woman. N-acetyl –beta –
glucosaminidine is an enzyme present in the lysosome of the 
renal tubules .The rise of N acetyl glucosaminidase is 
gestational age related  and  increases with increase in the 
gestational age. 
SERUM MARKERS 
Serum Inhibin A  
Serum Inhibin A measured in the first trimester is used 
as a predictor of preeclampsia, Serum  hCG  level  added to 
serum  inhibin did not give a better screening tool  for 
preeclampsia. Serum Inhibin A and  serum beta HCG are 
markers of the underlying impaired trophoblastic invasion 
.Serum  Inhibin  level measured alone  have a very low 
sensitivity and specificity. 
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Maternal Serum Alpha Fetoprotein (MSAFP) 
In many studies conducted using multivariate analysis 
using maternal serum alpha fetoprotein along with elevated 
mean arterial pressure,previous history of pre 
eclampsia,family history of preeclampsia,low serum oestriol 
levels and with the measurement of serum beta HCG levels 
has a predictive value with low sensitivity and specificity.            
Serum  Oestriol  
Serum oestriol is not used as a single predictive factor 
for the preeclampsia ,with the addition of several markers like 
HCG evaluation and alpha fetoprotein along with strong risk 
factors such as nulliparity, obesity(BMI>35), history of PIH 
in previous pregnancy, family histoy of preeclampsia 
contribute to the prediction of preeclampsia.  
Tumour necrosis factor of plasma was measured in 
patients with preeclampsia, TNF alpha levels were elevated in 
all the three trimesters of the pregnancy. Hence due to its 
universal elevation  throughout  pregnancy it cannot be used 
as a predictor that can used in first trimester and early second 
trimester to predict preeclampsia.                 
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Coagulation Factors and Platelets  
Thrombocytopenia , reduced levels of  clotting factors 
,evidence of platelet activation ,intravascular coagulation and 
haemolysis are present. 
In general lower the platelet count cause greater the 
maternal morbidity and mortality. Increased platelet 
consumption is evidenced by reduced platelet count, 
increased beta thromboglobulin levels  and elevated   platelet 
volume. Preeclamptic patients have increased antigen 
expression on their surface  during the first and second 
trimester of pregnancy and no tests can be used reliably for 
the prediction of preeclampsia based on platelet activation.  
Plasma fibronectin 
These high molecular weight glycoproteins serve a 
variety of functions such as adhesion, morphology , migration 
, phagocytosis and haemostasis .Fibronectins  are released 
from endothelial cells and extracellular matrix following 
endothelial injury. Stubbs and colleagues have demonstrated 
that plasma fibronectin levels were elevated in patients with 
preeclampsia. 
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Serum androgen markers and Sex Hormone Binding 
Globulin (SHBG) markers  
 Low levels of sex hormone binding globulin in early 
pregnancy was associated with later development of 
preeclampsia. When preeclamptic  patients were compared 
with normal pregnant women sex hormone binding globulin, 
serum testosterone, dehydroepiandrosterone sulphate showed 
no difference which is of statistically  significant. 
It has a better sensitivity than specificity for it to be a 
specific marker for preeclampsia but its negative predictive 
value is too low for as a predictor of preeclampsia.  
Serum  Thrombomodulin 
Serum thrombomodulin antigen levels were higher in 
patients with preeclampsia, chronic hypertension 
superimposed by preeclampsia, gestational hypertension and 
chronic hypertension. Serum thrombomodulin  levels  were 
higher in preeclampsia patients  than  patients  with 
gestational hypertension or chronic hypertension. Serum 
thrombomodulin  helps to differentiate preeclampsia from 
other hypertensive disorders of pregnancy. It is a better 
clinical marker compared to other biochemical markers.  
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Angiogenic factors in preeclampsia 
Several angiogeneic and anti angiogeneic factors are 
involved in the placental vascular development .An imbalance 
is in circulating  proangiogeneic(VEGF and PGF) and anti  
angiogeneic (soluble fms like tyrosine , soluble endoglin 
levels) factors. 
Elevated levels of soluble endoglin levels and soluble 
fms like tyrosine levels in second trimester have been 
associated with an increased risk of preeclampsia .These two 
anti angiogeneic factors are produced by the trophoblastic 
tissue of women destined to develop preeclampsia.  
Soluble fms like tyrosine levels 
Soluble fms like tyrosine levels are variant of placental 
growth factor and vascular endothelial growth factor and its 
increased levels decrease the PGF and VEGF levels leading 
to angiogeneic imbalance. 
Soluble Endoglin levels  
Soluble endoglin levels is a placenta derived molecule 
which causes decrease in the endothelium nitric oxide 
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dependent vasodilatation. The levels of both soluble fms like 
tyrosine levels and soluble endoglin levels in maternal 
circulation begin to raise months before the clinical syndrome 
of preeclampsia develops and dissipate after delivery.  
Since due to an excess of circulating anti angiogenic 
growth factors, most particularly soluble fms like tyrosine 
kinase 1 (sFlt1) and soluble endoglin (sEng)  hypertension 
and  proteinuria  develops.sFlt1 is an endogen which is able 
to bind to the vascular endothelial growth factor and placental 
growth factor(angiogeneic factors)and  therefore  abolish  
their  
actions. Soluble endoglin was found to help with the 
soluble form of vascular endothelial growth factor receptor 1 
in the pathogenesis of preeclampsia by inducing endothelial 
cell dysfunction. 
High serum concentrations of sFlt1 and low 
concentrations of free vascular endothelial growth factor and 
free placental growth factor were obvious clinically prior to 
clinical expression of preeclampsia. The disproportionate 
production of these two anti angiogenic proteins induce 
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endothelial dysfunction by preventing circulating 
proangiogenic factors for example the placental growth 
factor, the vascular endothelial growth factor but also the 
transforming growth factor beta. 
Oxidative stress factors 
Increased levels of lipid peroxides along with decreased 
anti oxidant activity have raised the possibility that markers 
of oxidative stress  might predict preeclampsia. A variety of 
pro-oxidants or potentiators of pro-oxidants including iron, 
transferrin, ferritin, blood lipids including triglycerides and 
free fatty acids are used as predictors of pre-eclampsia. 
Hyper homocystenemia  is associated with oxidative 
stress and endothelial dysfunction and hyper homocystenemia 
is associated with three to four fold increased risk of  
preeclampsia. 
Hence over many years, the methods and tests to predict 
preeclampsia prior to the appearance of the clinical disease 
has increased marginally not up to a remarkable level.  
None of the clinical laboratory, biochemical tests can 
be used for the prediction of the preeclampsia.  
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The preventive measures being used  for the prevention 
of preeclampsia, various serum tests and urinary  tests has 
been evaluated earlier has failed to establish itself as an 
predictor for patients with preeclampsia earlier than the 
clinical signs and symptoms has established. 
However in the future newer markers like s-Flt1, s-
Eng,VEGF and PIGF to predict the changes in the maternal  
cardiovascular system   preeclampsia before the clinical 
manifestation sets in .Hence now there is a absolute need in 
this decade to find a predictor and ideal screening test  due to 
the increased incidence of preeclampsia nowadays.  
Prevention of pre eclampsia  
It includes,  
Dietary manipulation- low salt diet, calcium 
supplementation, fish oil supplementation 
Cardiovascular drugs- diuretics, antihypertensive 
drugs, 
Antioxidants - absorbic acid (vitamin c),alpha 
tocopherol, 
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Antithrombotic drugs- low dose aspirin, 
aspirin/dipyridamole, aspirin with heparin, aspirin with 
ketanserin. 
DIETARY MANIPULATION 
Low Salt Diet 
One of the earliest research to prevent preeclampsia 
was salt restriction, studies conducted by knuist and 
colleagues showed that a sodium restricted diet  was 
ineffective in preventing preeclampsia. 
Calcium supplementation 
Studies performed in United States showed that women 
with low calcium intake were at significant risk of gestational 
hypertension in aggregate various trials show that unless 
women are calcium deficient supplementation has no salutary 
effects. 
Fish oil supplementation 
Cardioprotective fatty acids are found in some fatty 
fishes. The most common dietary sources are EPA-
eicosapentanoic acid and ALA –alpha linoleic acid. These 
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oils are helpful in preventing inflammatory  mediated  
atherogenesis. Several randomised trials show that there were 
no benefits to support this fish oil supplementation. 
Antihypertensives  
Because of the putative effects of sodium restriction it 
was not surprising that diuretics had a decreased incidence of 
oedema and hypertension but not preeclampsia. 
Anti oxidants 
Two naturally occurring antioxidants vitamin C and E 
may decrease such oxidation
24
 moreover women who develop 
preeclampsia were found to have reduced levels of these two 
vitamin. Thus dietary supplementation was proposed as a 
method to improve the oxidative capability of women at risk 
for preeclampsia.
27
  
Anti thrombotic drugs 
As discussed the syndrome is characterised by 
vasospasm, endothelial dysfunction and the activation of 
platelets and antithrombotic drugs can reduce the incidence of 
preeclampsia. 
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Low dose aspirin 
In oral doses of 50 to 150mg daily aspirin effectively 
inhibits platelet thromboxane biosynthesis with minimal 
effects on vascular prostacyclin  synthesis
26
. For women 
destined to receive anti platelet drug aspirin has 10% 
decreased risk of preeclampsia , superimposed preeclampsia, 
preterm delivery, or any pregnancy with an adverse outcome. 
The number needed to treat was high, hence it seems 
reasonable to individualise use of low dose aspirin  to prevent 
preeclampsia.  
A large randomised controlled trial ,the collaborative 
low dose aspirin study in pregnancy (CLASP) investigating 
the role of low dose aspirin used for the prevention of 
preeclampsia showed a non significant reduction of  
preeclampsia. Moreover the study showed that low dose 
aspirin was generally safe for the foetus and the neonates. 
Cochrane review showed 17% reduction in the risk of 
preeclampsia in high risk women and no benefit has been 
demonstrated for administrating low dose aspirin in low risk 
women. 
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Based on the clinical evidence National institute of 
clinical excellence UK recommends 75mg of aspirin for all 
women at high risk of preeclampsia from 12 weeks until the 
birth of the baby.  
Low dose aspirin and heparin 
Because of the high prevalence of placental thrombotic 
lesions with severe preeclampsia there were many 
observational studies to evaluvate the effect of heparin. Many 
studies reviewed that low molecular heparin with low dose 
aspirin have a beneficial effect in women with a history of 
severe early onset preeclampsia and low birth weight infants. 
Rest and Reduce Physical Activity 
Cochrane review included trials which investigated the 
effect of rest or reduced physical activity in normal pregnant 
women who are risk of preeclampsia from 28 to 32 weeks and 
it showed that rest couldn’t be recommended as a 
prophylactic intervention to prevent the preeclampsia.   
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THE  PERFECT SCREENING TEST 
 Simple 
 Non invasive 
 Rapid 
 Inexpensive 
 Easy to perform early in pregnancy 
 Highly sensitivity & predictive                             
 HUMAN CHORIONIC GONADOTROPIN  
Human chorionic gonadotropin (HCG) is a pregnancy 
hormone with biological similar to luteinizing hormone. Both 
act via through plasma membrane LH, HCG receptor. 
Hormone is produced by the syncytiotrophoblast cells after 
implantation in myometrium. Most cancer cells produce this 
hormone, increased levels may be used as a diagnostic and 
prognostic factor in diagnosis. The HCG component of 
pituitary is analogous to luteinizing hormone (LH) and it is 
present in the pituitary gland of all human beings at all ages. 
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STRUCTURE 
Chorionic gonadotrophins is a glycoprotein with 
molecular weight of 36,000 to 40,000 Da. It has the highest 
carbohydrate content of any hormone about 30 percent .The 
carbohydrate component and especially the terminal sialic 
acid , protects the molecule from catabolism. The 36 hour 
plasma half life of intact HCG is much longer than the 2 
hours for LH  
The HCG molecule has two dissimilar subunits, one is 
designated alpha and is composed of 92 amino acids ,whereas 
beta subunit contains 145 aminoacids .These are non 
covalently linked and are held together by electrostatic and 
hydrophobic forces .Isolated subunits are unable to bind the 
LH receptor and lack biological activity.  
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Structure of Beta HCG molecule 
 
FUNCTION 
             Both HCG subunits are required for binding to 
the LH-HCG receptor in the corpus luteum  and the foetal 
testis .Best known biological function of HCG is maintenance 
of the corpus luteum.HCG stimulates foetal testicular 
testosterone secretion which is maximum when the peak 
levels of  HCG levels are obtained. 
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It is well established  that HCG act as a  placental link 
for the   maternal immunological process .For example HCG 
treated cells of the endometrium  have been used in the 
treatment of cancer cells. 
HCG is linked with the development of 
peritrophoblastic  immune  tolerance, and for the trophoblast 
invasion  and it is also raised in patients with hyperemesis  
gravidaram. HCG levels correlate well with of morning 
sickness in early pregnancy.  
HCG since it has a resemblance with the LH level in the 
pituitary it is used to detect ovulation process as well as 
testosterone production in the testes. Since the source of HCG 
is pregnant women urine ,marketing companies prefer to 
obtain  urine to use them in the treatment of infertility. HCG 
trigger apoptosis and play a role in cell proliferation and 
differentiation, helps to promote apoptosis. 
BIOSYNTHESIS 
Both alpha and beta chain synthesis of HCG are 
regulated separately. A single gene located on chromosome 6 
encodes the alpha subunit for HCG,LH, FSH and TSH. Both 
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subunits are synthesised as large precursors, which are 
cleaved by endopeptidase  and intact HCG is then assembled 
and rapidly released by exocytosis of secretary granules. 
SITE OF HCG SYNTHESIS 
Before 5 weeks HCG is expressed in both 
syncytiotrophoblast and cytotrophoblast and later when serum 
beta HCG level is peak , it is almost solely produced by 
syncytiotrophoblast. At this time HCG mRNA for both alpha 
and beta subunits are greater than at term .This may be 
important consideration when HCG is used as a screening 
procedure to identify abnormal foetus.  
REGULATION OF HCG SYNTHESIS 
Placental GnRH  is involved in the regulation of HCG 
formation, both GnRH  and its receptor are expressed on 
cytotrophoblast and syncytiotrophoblast .Also GnRH 
administration elevates the circulating HCG levels and 
cultured trophoblastic cells respond to GnRH  treatment with 
increased HCG secretion.Pituitary GnRH  production also is 
regulated by inhibin and activin. In cultured Placental cells 
activin stimulates and inhibin will inhibits GnRH and HCG 
production. 
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METABOLIC CLEARANCE OF HCG 
Renal clearance of  HCG accounts for 30% of its 
clearance ,the reminder is likely cleared by metabolism in the 
liver.Clearances of beta and alpha subunit are about 10-fold 
and 30-fold respectively greater than that of intact HCG. By 
contrast renal clearance of these subunits is considerably 
lower than that of dimeric HCG. 
METHODOLOGY 
Tests used to identify the HCG levels in serum mostly 
use monoclonal antibody. This procedure usually is used 
since these do not give false positive results by its 
resemblance with LH & FSH. HCG assays are used on the 
principle of sandwich method which detects HCG using 
antibodies linked to enzyme or luminescent dye. It can also 
be detected by chemiluminescent method , lateral flow 
technique also detects HCG linked on a dipstick. 
Early morning urine samples are taken to detect the beta 
HCG levels since early morning urine sample have the 
highest levels of beta HCG when the specific gravity of the 
urine sample is low due to diluted urine , HCG could not be 
detected in the urine sample. 
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Chemiluminescent assay and fluorometric assays detect 
beta HCG levels when the serum sample size of 2 to 4 ml is  
drawn , and hence quantification of serum beta HCG levels 
according to the gestational age can be done. 
MOLECULAR FORMS OF HCG IN PLASMA AND 
URINE 
Free subunits   
Circulating free beta subunits are too low to become 
undetectable throughout pregnancy .This is the result of its 
rate limiting synthesis .Free alpha subunit are found in 
placental tissue and maternal plasma .These levels increase 
gradually and steadily until they plateau at about 36 weeks. 
At this time they account for from 30 to 50 %of hormone 
.Thus alpha HCG secretion roughly corresponds to placental 
mass ,whereas secretion of complete HCG molecules is 
maximal at 8 to 10 weeks. 
Concentration   of HCG in serum and urine  
The intact HCG molecule is detected in the plasma of 
pregnant women 7 to 9 days after the mid cycle surge of LH 
precedes ovulation. Thus it is likely that HCG enters maternal 
blood at the time of blastocyst implantation .Plasma levels 
 46 
increase rapidly and doubling every 2 days with maximal 
levels being attained at 8 to 10 weeks. 
The pattern of HCG appearance in foetal blood is 
similar to that in the mother. Foetal plasma levels however 
are only about 3% of those in maternal plasma level. As  
pregnancy progresses  HCG concentration in amniotic fluid 
declines and near term the levels are about 20% of those in 
maternal plasma.        
Reference values in normal pregnant woman 
The HCG levels increase after conception and peak 
plasma levels about 1,00,000 m IU/ ml between the 60
th
 and 
80
th
 days after LMP. At 10 to 12 weeks plasma levels begin to 
decline and a nadir is reached by about 16 weeks. Plasma 
levels are maintained at this lower level for the reminder of 
the pregnancy. 
Weeks of gestation   HCG levels (mIU/ml) 
4 45 
6 350 
15  7230 
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1,500  55,000 
75,560 232,000 
11,35,725 299,000 
17,12,200 224,000 
255,080  155,425 
404,720  1,24,000  
Serum beta HCG levels estimation done by CLIA 
method. 
The Multiples of median was calculated from the 
median of the diagnostic study. Beta HCG levels are said to 
be elevated if levels raised more than 2MOM. Follow up of 
AN mothers done till third trimester by monitoring blood 
pressure and proteinuria .Prediction of PIH done according to 
the  elevated beta HCG level. Severity of the PIH is classified 
according to the elevated beta HCG levels. 
MANAGEMENT OF  PREECLAMPSIA 
Ideally all patients with mild preeclampsia is 
hospitalised once diagnosis is made. All patients receive a 
regular diet with no salt restriction and no activity limits. The 
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blood pressure should be measured for every 4hours and the 
patients should be assessed for their weight and oedema. Also 
24 hour urine collection for protein excretion, haematocrit, 
platelet count and liver function test should be done. 
For the less than 37 weeks but the presence of 
persistent hypertension, protenuria, abnormal lab values, 
abnormal foetal growth and unreliable patient admit the 
patient for further management.When the above mentioned 
factors were absent, they were managed in home with 
frequent evaluations of BP and urine. 
For the patients with more than 37weeks, favourable 
cervix, foetal jeopardy, visual disturbances and persistent 
headache treatment with MgSO4 and delivery should be done.  
MATERNAL MONITORING
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1) Blood pressure every 4 hours during the day 
2) Presence of facial or abdominal oedema. 
3) Measure the weight daily 
4) Haematocrit and platelet count twice a week 
5) LFT 1-2 times a week 
6) Symptoms of impending eclampsia 
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FOETAL MONITORING
43 
1) Daily foetal movements 
2) NST 3 times a week 
3) Biophysical profile if NST – ve 
4) USG evaluation of foetal growth every 3-4 weeks 
INDICATIONS FOR TERMINATION  IN  
PREECLAMPSIA
29 
Maternal Indications 
1) Persistent increase in BP to severe level(>160 systolic 
and >110 diastolic) 
2) Development of persistent cerebral symptoms 
(imminent   symptoms) 
3) HELLP syndrome 
4) Onset of  labour,Rupture of membrane or bleeding 
FOETAL INDICATIONS 
1) Severe IUGR by USG 
2) Non reactive NST with abnormal biophysical profile 
3) Development of oligohydramnios 
4) Gestational age 38-40 weeks  
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INTRAPARTUM MANGEMENT
44 
 Maternal Analgesia-Intermittent use of small doses-25 to 
50mg  IV Meperidine or segmental epidural analgesia. 
 Empiric Antihypertensive therapy recommended for 
more than 160/110mmHg. 
 Diuretics are not needed except in the presence of 
pulmonary edema and this may exacerbrate the 
maternal cerebral ischaemia ,decrease the renal function 
and jeopardise the foetal well being. 
POSTPARTUM MANAGEMENT 
After delivery the patient should continue to be 
monitored and the patient should be seen at weekly intervals 
until blood pressure is in normal range without medication.  
REMOTE FROM TERM 
 Uncontrolled severe hypertension 
 Eclampsia 
 Platelet count <1,00,000mm^3 
 Pulmonary oedema 
 Compensatory renal function 
 Abruptio placentae 
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   Consider Expectant Management  
 Controlled Hypertension 
 Urinary protein of any amount 
 Oliguria(<0.5ml/kg/hr) which resolves with routine 
fluid and food intake 
 AST or ALT >2 x upper limits of normal without 
epigastric or right upper quadrant tenderness   
Foetal Indication 
 Expeditious delivery within 72 hours 
 One or more of the following 
 Repetitive or severe variable deceleration 
 Biophysical profile <4 on two occasions 4 hrs apart 
 AFI<2 
 USG estimation of foetal weight <5 th percentile 
 Reduced umbilical artery diastolic flow.      
TREATMENT 
Anti Hypertensives in Preeclampsia 
The guidelines to start anti hypertensives in non severe 
hypertension is to maintain systolic BP at 130-155mmHg and 
diastolic BP at 80 -105mmHg in women without comorbid 
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factors.In those without comorbidities,systolic BP should be 
kept at 130-139mmHg and diastolic BP at 80-89mmHg. 
The most  common first line oral drugs used to treat 
non evere hypertension are labetalol42 and methyldopa.If 
adequate control is not attained by first line drugs,then 
second line drugs such as calcium channel blockers ,beta 
blockers like metaprolol, acebutol and propanolol are used. 
ALPHA METHYL DOPA 
The commonest first choice of drug used to control 
hypertension  due to its long safety record.This drug is a 
centrally acting drug an alpha adrenergic agonist .It decreases 
the sympathetic tone and blood pressure.It is started at a 
initial dose of 250 to 500mg  2-3 times a day upto a 
maximum dose of 2gm/day.  
The maximum drug effect occurs at 4 to6 hours and it 
persists for 12 hours.  
MATERNAL SIDE EFFECTS 
Postural hypotension,lethargy,dry mouth,drug induced 
hepatitis and very rarely haemolytic jaundice.  
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FOETAL SIDE EFFECTS   
Although methyl dopa crosses the placenta and almost 
100% secreted in the milk secretion but has no teratogenecity.  
LABETOTOL 
Labetolol43 has both alpha and beta blocking actions. 
Its is started at a dose of 100mg to 400mg upto a 
maximum of 1200 mg/day.Labetolol has replaced nowadays 
alpha methyl dopa as a first line therapy. Due to its beta 
blocking property it usually masks the signs of 
hypoglycaemia in patients treated with insulin therapy.  
MATERNAL SIDE EFFECTS  
Dizziness, drowsiness, fatigue, bradycardia, insomnia, 
shortness of breath, nausea, vomiting. 
FOETAL SIDE EFFECTS 
Hypoglycaemia, neonatal hyperbilirubinemia, IUGR 
NIFEDIPINE 
It is a calcium channel blocker and it is used in patients 
who do not attain adequate control with first line drugs. 
Dose;10-20mg tds, Maximum dose 180mg per day. Side 
effects include headache, dizziness, palpitation, nasal congestion. 
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INDICATION OF DIURETICS 
It is not routinely used in preeclampsia due to depletion 
of intravascular volume. It is used only special situations like 
congestive cardiac failure,actue pulmonary oedema,increased 
cerebral vascular tension. 
MGSO4  FOR ECLAMPSIA 
1) Pitchard Regimen; 
a. 10gm loading dose followed by 5gm every 4hours 
2) Continuous intravenous infusion-Zuspan,4 gm loading 
dose followed by 1gm/hr 
3) Sibai: 6 gm loading dose followed by 2gm/hr 
Approximate serum levels of  Mg;  3.5-7mg/L or 
4.2-8.4 mEq/dl 
Effects of MgSO4 Therapy
42 
Beneficial effects 
 Vasodilatation in vascular beds 
 Increased uterine blood  flow 
 Increased renal blood flow 
 Increased  prostacyclin  release by endothelial cells 
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 Decreased plasma rennin activity 
 Decreased Angiotensin converting enzyme levels 
 Attenuation of vascular response to pressor 
substances 
 Bronchodilatation  
 Decreased platelet aggregation 
DETRIMENTAL EFFECTS 
 Decrease the uterine activity and causes  prolonged 
labour 
 Decrease the  foetal heart rate variability 
 Increase the blood loss after delivery 
 Neonatal neuromuscular and respiratory depression 
 Low APGAR score. 
Mg Level(mg/dl) Findings 
      1.5 - 2.5 Normal level 
       5 -   8 Therapeutic range for severe prophylaxis    
       9 – 12 Loss of patellar reflex 
      14 – 17 Muscular paralysis & Respiratory arrest   
      28 – 35 Cardiac arrest.  
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MATERIALS AND METHODS 
Duration of the Study : January 2014 —October 2014 
Type: Prospective Randomized Control trial 
Place: Department of Obstetrics & Gynaecology, 
Institute Of Obstetrics And Gynecology,Egmore,Chennai.  
INCLUSION CRITERIA  
All normotensive non proteinuric pregnant women  
selected randomly between gestational age 13 to 20 weeks 
attending AN clinics irrespective of parity.  
EXCLUSION CRITERIA 
 Women with Multiple pregnancy  
 Essential hypertension  
 Diabetes mellitus  
 Molar pregnancy 
Institutional Ethics Committee approval was obtained 
with EC NO:15022014. 
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Informed consent was taken from all patients who 
underwent the study.All the patients details were recorded as 
per the Proforma( Appendix A). All Antenatal patients 
attending antenatal clinics in the inclusion criteria has been 
selected between the gestational age13 to 20 weeks and serum 
Beta HCG levels were taken for them.Complete history of the 
patient was taken and through clinical examination was done 
for all patients. 
Gestational age of the patient was confirmed by the 
crown rump length measurement in the first trimester by 
dating scan at 7 week. All patients were advised congenital 
anomaly USG at 20-22 weeks. All the basic investigation 
including blood grouping were taken.                       
All these patients were followed upto their third trimester 
by the blood pressure evaluation,proteinuria and allocated into 
three groups with no PIH,mild PIH and severe PIH. 
 Serum beta HCG levels estimation done by CLIA 
method.  
 The Multiples of median was calculated from the 
median of the diagnostic study. 
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 Beta HCG levels are said to be elevated if levels raised 
more than 2MOM.  
 Prediction of PIH done according to the  elevated beta 
HCG levels. 
 Severity of the PIH was classified  according to the 
elevated beta HCG levels. 
 Prediction of PIH based on parameters like 
Age,Parity,Gestational Age,Body Mass Index and the 
Past History of PIH. 
STATISTICAL ANALYSIS 
Descriptive statistics were used to illustrate the study 
population. The statistical significance of these correlations 
was assessed using a two sided p-value.  A p-value of <0.05 
was considered as statistically significant. The Chi Square 
test and ANOVA test were  used to assess the statistical 
significance. Multiple comparision test and paired T test  are 
also used for the comparision of various descriptive within 
the groups. A commercially available computer software 
package (Statistical Package for the Social  Sciences (SPSS) 
version 17) was used for statistical analysis.  
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RESULTS 
AGE GROUP ;NO PIH-0,MILD PIH-1,SEVERE PIH-2 
   PIH  
   0 1 2 Total 
Age 
Group 
1 Count 60 25 12 97 
% within 
Age Group 
61.9% 25.8% 12.4% 100.0% 
% within 
PIH 
44.8% 55.6% 57.1% 48.5% 
% of Total 30.0% 12.5% 6.0% 48.5% 
2 Count 74 20 9 103 
% within 
Age Group 
71.8% 19.4% 8.7% 100.0% 
% within 
PIH 
55.2% 44.4% 42.9% 51.5% 
% of Total 37.0% 10.0% 4.5% 51.5% 
 Total Count 134 45 21 200 
% within 
Age Group 
67.0% 22.5% 10.5% 100.0% 
% within 
PIH 
100.0% 100.0% 100.0% 100.0% 
% of Total 67.0% 22.5% 10.5% 100.0% 
Chi squre= 2.269     P=0.322   not significant. 
Out of 200 patients, 97 patients belong to age group 
below 25,60 patients(61.9%)  had no PIH ,25 patients(25.8%)  
had mild PIH,12 patients (12.4%) had severe PIH. 
103 patients belong to age group above 25 and 74 
patients(71.8%)had no PIH,20 patients (19.4%)had mild PIH 
and 9 patients (8.7%) had severe PIH.  
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CHI-SQUARE TESTS 
 Value df Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 2.269a 2 .322 
Likelihood Ratio 2.272 2 .321 
Linear-by-Linear 
Association 
2.024 1 .155 
N of Valid Cases 200   
0 cells (.0%) have expected count less than 5. The 
minimum expected count is 10.19. 
According to chi square tests correlation between age 
and occurrence of preeclampsia  have no significance since 
expected count is less than 5 .Age groups do not have 
significant correlation with the development of preeclampsia. 
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Group 1-Age <25 years, Group 2-Age >25 years. 
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AGE GROUP  <25 YEARS - GROUP 1, >25 YEARS - 
GROUP 2 
 
PIH GROUP  0-NO, 1-MILD, 2-SEVERE 
Crosstab 
 
95% Confidence 
Interval for Mean 
 N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
0 134 25.61 2.138 .185 25.25 25.98 
1 45 24.60 3.306 .493 23.61 25.59 
2 21 25.14 3.021 .659 23.77 26.52 
Total 200 25.34 2.562 .181 24.98 25.69 
AGE 
 Minimum Maximum 
0 21 31 
1 19 31 
2 19 32 
Total 19 32 
Age groups without PIH are between 21 and 31years , 
age groups with mild PIH are between 19 and 31 years,age 
groups with severe PIH are between 19 and 32 years.  
Age doesn’t have any significance for the occurrence of PIH. 
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MULTIPLE COMPARISIONS 
AGE; 0-NO PIH, 1-MILD PIH, 2-SEVERE PIH 
(I) 
PIH 
(J) 
PIH 
 
95% Confidence 
Interval 
Mean 
Difference (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
0 1 1.012* .438 .022 .15 1.88 
2 .469 .596 .432 -.71 1.64 
1 0 -1.012* .438 .022 -1.88 -.15 
2 -.543 .671 .420 -1.87 .78 
2 0 -.469 .596 .432 -1.64 .71 
1 .543 .671 .420 -.78 1.87 
The mean difference is significant at the 0.05 
level.There is no significant difference when the age is 
compared between the groups. 
MEANS PLOTS 
 
Mean age for patients without PIH group (0) - 25.61 . 
Mean age for patients with mild PIH group (1) - 24.60 . 
Mean age for patients with severe PIH group (2)- 25.14 
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GESTATIONAL AGE 
No PIH – 0, Mild PIH – 1, Severe PIH - 2 
  
95% Confidence 
Interval for Mean 
 N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
0 134 15.75 1.629 .141 15.48 16.03 
1 45 15.20 1.618 .241 14.71 15.69 
2 21 15.24 1.411 .308 14.60 15.88 
Total 200 15.58 1.618 .114 15.35 15.80 
Mean gestational age for no PIH, mild PIH, severe PIH 
is 15.75,15.20 and 15.24  respectively. Mean gestational age 
for the study is 15.58. 
GEST. AGE (WKS) 
 Minimum Maximum 
0 13 19 
1 12 19 
2 13 19 
Total 12 19 
Age group between the ages 13 and 19 with no PIH. 
Age group between the ages 12 and 19 with mild PIH. Age 
group between the ages 13 and 19 with severe PIH. 
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GESTATIONAL AGE(WKS)-ANOVA 
 
Sum of 
Squares 
Df 
Mean 
Square 
F Sig. 
Between Groups 12.992 3 6.496 2.520 .083 
Within Groups 507.883 197 2.578   
Total 520.875 200    
According to anova analysis correlation between the 
gestational age and occurrence of PIH is insignificant with a 
P value of 0.083. 
GEST.AGE(WKS)-MULTIPLE COMPARISIONS 
(I) 
PIH 
(J) 
PIH 
 
95% Confidence 
Interval 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
0 1 .554* .277 .047 .01 1.10 
2 .516 .377 .173 -.23 1.26 
1 0 -.554* .277 .047 -1.10 .00 
2 -.038 .424 .929 -.87 .80 
2 0 -.516 .377 .173 -1.26 .23 
1 .038 .424 .929 -.80 .87 
The mean difference is significant at the 0.05 level. 
When the gestational age is compared between the 
groups, there is no significant p value. 
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Mean age for patients without PIH -15.75 
Mean age for patients with mild PIH-15.24  
Mean age for patients with severe PIH-15.58 
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SERUM BETA HCG LEVELS 
  
95% Confidence 
Interval for Mean 
 N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
0 134 71205.60 12483.383 1078.400 69072.57 73338.64 
1 45 101178.49 37804.364 5635.542 89820.80 112536.18 
2 21 154560.05 27929.414 6094.698 141846.73 167273.36 
Total 200 86701.72 34547.956 2442.909 81884.41 91519.03 
Out of 200 patients,134 patients had no PIH had mean 
beta hcg levels of 71205, 45 patients had mild PIH with the 
beta hcg level of 101178 and 21 patients had severe PIH with 
the mean beta hcg levels of 154560. 
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SERUM BETA HCG 
 Beta Hcg Level 
Group Minimum Maximum 
0 36092 142000 
1 51906 186214 
2 96999 197650 
Total 36092 197650 
Patients without PIH have a serum beta hcg levels 
ranging between 36,092 and 1,42,000. Patients with mild PIH 
have serum beta hcg levels ranging between 51,906 and  
1,86,214. Patients with severe PIH have a serum beta hcg 
levels ranging between 96,999 and1,97,650. 
SERUM BETA HCG-ANOVA 
 
Sum of 
Squares 
Df 
Mean 
Square 
F Sig. 
Between 
Groups 
1.383E11 3 6.915E10 137.318 .000 
Within Groups 9.921E10 197 5.036E8   
Total 2.375E11 199    
Anova analysis of serum beta hcg values of patients 
between the groups and within the groups have a significant p 
value of 0.000. 
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MULTIPLE COMPARISONS 
 SERUM BETA HCG BETWEEN THE GROUPS 
(I) 
PIH 
(J) 
PIH 
 
95% Confidence 
Interval 
Mean 
Difference  
(I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
0 1 -29972.884* 3866.461 .000 -37597.85 -22347.92 
2 -83354.443* 5266.834 .000 -93741.06 -72967.83 
1 0 29972.884* 3866.461 .000 22347.92 37597.85 
2 -53381.559* 5930.645 .000 -65077.26 -41685.86 
2 0 83354.443* 5266.834 .000 72967.83 93741.06 
1 53381.559* 5930.645 .000 41685.86 65077.26 
*. The mean difference is significant at the 0.05 level.  
Comparisons of patients without PIH and patients with 
mild and severe PIH have a p value 0.0 in correlation of Beta 
HCG levels which is very significant.  
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MEANS PLOTS 
 
Mean value of serum beta hcg level in patients without 
PIH –71,205.60 mIU/ml. Mean value of serum beta hcg level 
in patients with mild PIH –1,01,178.49 mIU/ml. Mean value 
of serum beta hcg level in patients with severe PIH – 
1,54,560.05 mIU/ml. 
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ROC CURVE 
SR.BHCG
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
S
e
n
s
it
iv
it
y  Sensitivity: 68.2
 Specificity: 96.3
 Criterion : >89904
 
Variable SR.BHCG 
Classification variable PIH 
   
Sample size  200 
Positive group :  PIH = 1 66 
Negative group :  PIH = 0 134 
   
Disease prevalence (%) unknown 
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 Area under the ROC curve (AUC)  
 Area under the ROC curve (AUC)  0.828924 
Standard Error 0.0390 
95% Confidence intervalb 0.769440 to 0.878374 
z statistic 8.430 
Significance level P (Area=0.5) <0.0001 
 
YOUDEN INDEX 
 Youden index J 0.6445 
Associated criterion >89904 
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CRITERION VALUES AND COORDINATES OF THE  
ROC CURVE  
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
≥36092 100.00 94.6 - 100.0 0.00 0.0 - 2.7 1.00  
>50108 100.00 94.6 - 100.0 2.99 0.8 - 7.5 1.03 0.00 
>51906 98.48 91.8 - 100.0 2.99 0.8 - 7.5 1.02 0.51 
>52608 98.48 91.8 - 100.0 4.48 1.7 - 9.5 1.03 0.34 
>52806 96.97 89.5 - 99.6 4.48 1.7 - 9.5 1.02 0.68 
>52908 96.97 89.5 - 99.6 5.22 2.1 - 10.5 1.02 0.58 
>54108 95.45 87.3 - 99.1 5.22 2.1 - 10.5 1.01 0.87 
>55606 95.45 87.3 - 99.1 6.72 3.1 - 12.4 1.02 0.68 
>56124 92.42 83.2 - 97.5 6.72 3.1 - 12.4 0.99 1.13 
>56786 92.42 83.2 - 97.5 8.21 4.2 - 14.2 1.01 0.92 
>56980 89.39 79.4 - 95.6 8.21 4.2 - 14.2 0.97 1.29 
>64567 89.39 79.4 - 95.6 26.87 19.6 - 35.2 1.22 0.39 
>64623 87.88 77.5 - 94.6 26.87 19.6 - 35.2 1.20 0.45 
>67706 87.88 77.5 - 94.6 35.07 27.0 - 43.8 1.35 0.35 
>67802 86.36 75.7 - 93.6 35.07 27.0 - 43.8 1.33 0.39 
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Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
>68806 86.36 75.7 - 93.6 44.03 35.5 - 52.9 1.54 0.31 
>68902 84.85 73.9 - 92.5 45.52 36.9 - 54.3 1.56 0.33 
>71704 84.85 73.9 - 92.5 49.25 40.5 - 58.0 1.67 0.31 
>71924 83.33 72.1 - 91.4 49.25 40.5 - 58.0 1.64 0.34 
>74804 83.33 72.1 - 91.4 63.43 54.7 - 71.6 2.28 0.26 
>74806 81.82 70.4 - 90.2 64.18 55.4 - 72.3 2.28 0.28 
>76000 81.82 70.4 - 90.2 68.66 60.1 - 76.4 2.61 0.26 
>76101 80.30 68.7 - 89.1 68.66 60.1 - 76.4 2.56 0.29 
>77404 80.30 68.7 - 89.1 72.39 64.0 - 79.8 2.91 0.27 
>78124 77.27 65.3 - 86.7 72.39 64.0 - 79.8 2.80 0.31 
>78802 77.27 65.3 - 86.7 75.37 67.2 - 82.4 3.14 0.30 
>78804 75.76 63.6 - 85.5 77.61 69.6 - 84.4 3.38 0.31 
>78965 75.76 63.6 - 85.5 83.58 76.2 - 89.4 4.61 0.29 
>79102 74.24 62.0 - 84.2 83.58 76.2 - 89.4 4.52 0.31 
>80608 74.24 62.0 - 84.2 87.31 80.5 - 92.4 5.85 0.30 
>81806 71.21 58.7 - 81.7 87.31 80.5 - 92.4 5.61 0.33 
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Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
>85503 71.21 58.7 - 81.7 92.54 86.7 - 96.4 9.54 0.31 
>86704 68.18 55.6 - 79.1 92.54 86.7 - 96.4 9.14 0.34 
>89904 68.18 55.6 - 79.1 96.27 91.5 - 98.8 18.27 0.33 
>90961 66.67 54.0 - 77.8 96.27 91.5 - 98.8 17.87 0.35 
>95904 66.67 54.0 - 77.8 97.76 93.6 - 99.5 29.78 0.34 
>96708 60.61 47.8 - 72.4 97.76 93.6 - 99.5 27.07 0.40 
>96786 60.61 47.8 - 72.4 98.51 94.7 - 99.8 40.61 0.40 
>96999 59.09 46.3 - 71.0 98.51 94.7 - 99.8 39.59 0.42 
>98750 59.09 46.3 - 71.0 99.25 95.9 - 100.0 79.18 0.41 
>135906 37.88 26.2 - 50.7 99.25 95.9 - 100.0 50.76 0.63 
>142000 37.88 26.2 - 50.7 100.00 97.3 - 100.0  0.62 
>197650 0.00 0.0 - 5.4 100.00 97.3 - 100.0  1.00 
In this study out of 200 patients 66 patients were with 
PIH and 134 patients were without PIH ,which had sensitivity 
of 68.2 and specificity of 96.3 and significant p value of 
<0.0001. 
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Variable SR.BHCG 
Classification variable PIH 
   
Sample size   155 
Positive group :  PIH = 1 21 
Negative group :  PIH = 0 134 
   
Disease prevalence (%) Unknown 
    
YOUDEN INDEX 
Youden index J 0.9851 
Associated criterion >96786 
   
Area under the ROC curve (AUC)  0.997512 
Standard Errora 0.00235 
95% Confidence intervalb 0.971611 to 1.000000 
z statistic 211.275 
Significance level P (Area=0.5) <0.0001 
 78 
CRITERION VALUES AND COORDINATES OF THE  
ROC CURVE  
Criterion values and coordinates of the ROC curve  
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
≥36092 100.00 83.9 - 100.0 0.00 0.0 - 2.7 1.00  
>96786 100.00 83.9 - 100.0 98.51 94.7 - 99.8 67.00 0.00 
>96999 95.24 76.2 - 99.9 98.51 94.7 - 99.8 63.81 0.048 
>98750 95.24 76.2 - 99.9 99.25 95.9 - 100.0 127.62 0.048 
>135906 71.43 47.8 - 88.7 99.25 95.9 - 100.0 95.71 0.29 
>142000 71.43 47.8 - 88.7 100.00 97.3 - 100.0  0.29 
>197650 0.00 0.0 - 16.1 100.00 97.3 - 100.0  1.00 
When the prediction of severe PIH based on maternal 
serum Beta HCG had 100% sensitivity and 98.5%specificity 
with significant p value. 
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PARITY * PIH 
   PIH 
Total 
   0 1 2 
Parity 1 Count 97 29 15 141 
% within 
PARITY 
68.8% 20.6% 10.6% 100.0% 
% within PIH 72.4% 64.4% 71.4% 70.5% 
% of Total 48.5% 14.5% 7.5% 70.5% 
2 Count 32 11 5 48 
% within 
PARITY 
66.7% 22.9% 10.4% 100.0% 
% within PIH 23.9% 24.4% 23.8% 24.0% 
% of Total 16.0% 5.5% 2.5% 24.0% 
3 Count 5 4 1 10 
% within 
PARITY 
50.0% 40.0% 10.0% 100.0% 
% within PIH 3.7% 8.9% 4.8% 5.0% 
% of Total 2.5% 2.0% .5% 5.0% 
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   PIH 
Total 
   0 1 2 
4 Count 0 1 0 1 
% within 
PARITY 
.0% 100.0% .0% 100.0% 
% within PIH .0% 2.2% .0% .5% 
% of Total .0% .5% .0% .5% 
 Total Count 134 45 21 200 
% within 
PARITY 
67.0% 22.5% 10.5% 100.0% 
% within PIH 100.0% 100.0% 100.0% 100.0% 
% of Total 67.0% 22.5% 10.5% 100.0% 
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BODY MASS INDEX 
  
95% Confidence 
Interval for Mean 
 N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
0 134 25.15 3.486 .302 24.55 25.75 
1 45 25.18 3.540 .534 24.10 26.26 
2 21 25.86 3.787 .847 24.09 27.64 
Total 200 25.23 3.517 .251 24.73 25.72 
Out of 200 patients 134 patients who had no pih had a 
mean BMI 25.15 45 patientswho had mild pih  had a BMI of 
25.18 21patients who had severe pih had a BMI of 25.86.  
BMI 
 Minimum Maximum 
0 19 32 
1 19 32 
2 20 33 
Total 19 33 
Of  patients without PIH and with mild PIH had BMI 
between 19 and  32, patients with severe PIH had range 
between 20 and 33. 
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BMI-ANOVA 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 9.015 4 4.507 .362 .697 
Within Groups 2415.663 196 12.452   
Total 2424.678 200    
In anova analysis within the group and between the 
groups BMI had no significance. 
MULTIPLE COMPARISONS- BODY MASS INDEX 
(I) 
PIH 
(J) 
PIH 
 
95% Confidence 
Interval 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
0 1 -.032 .614 .959 -1.24 1.18 
2 -.715 .846 .399 -2.38 .95 
1 0 .032 .614 .959 -1.18 1.24 
2 -.683 .952 .474 -2.56 1.19 
2 0 .715 .846 .399 -.95 2.38 
1 .683 .952 .474 -1.19 2.56 
Comparison of  BMI of  patients without PIH with the 
BMI  of patients with mild PIH and severe PIH have a p value 
of insignificant level 0.959 and 0.399. 
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Comparison of  BMI of patients with mild PIH with 
BMI of patients without PIH and severe PIH  have a p value 
of insignificant level 0.959 and 0.474. 
Comparison of BMI of patients with severe PIH with 
BMI  of patients without PIH and mild PIH have a p value of 
insignificant level 0.399and 0.474. 
So,body mass index does not have significant 
correlation with the development of PIH.   
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MEANS PLOTS 
 
Mean BMI value of patients without PIH -25.15 
Mean BMI value of patients with mild PIH -25.18 
Mean BMI value of patients with severe PIH -25.86  
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PREVIOUS LSCS  
Crosstab 
   PIH  
   0 1 2 Total 
PRE. 
LSCS 
N Count 122 38 17 177 
% within 
PRE.LSCS 
68.9% 21.5% 9.6% 100.0% 
% within PIH 91.0% 84.4% 81.0% 88.5% 
% of Total 61.0% 19.0% 8.5% 88.5% 
Y Count 12 7 4 23 
% within 
PRE.LSCS 
52.2% 30.4% 17.4% 100.0% 
% within PIH 9.0% 15.6% 19.0% 11.5% 
% of Total 6.0% 3.5% 2.0% 11.5% 
 Total Count 134 45 21 200 
% within 
PRE.LSCS 
67.0% 22.5% 10.5% 100.0% 
% within PIH 100.0% 100.0% 100.0% 100.0% 
% of Total 67.0% 22.5% 10.5% 100.0% 
Out of 200 patients with the previous LSCS were 23 
patients, of which 12 patients(52.2%) had no PIH ,7 patients 
(30.4%)had mild PIH ,4 patients( 17.4%)had severe PIH.  
Without previous LSCS were 177 patients,of which 122 
patients(68.9%)had no PIH ,38 patients(21.5%)had mild PIH 
and 17 patients(9.6%) had severe PIH.  
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CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 2.755a 2 .252 
Likelihood Ratio 2.584 2 .275 
N of Valid Cases 200   
a. 1 cells (16.7%) have expected count less than  
5. The minimum expected count is 2.42.Chi-Square test 
showed that there was no significant difference by the 
previous history of LSCS on the development of PIH. 
 
Patients with previous scar and patients without 
previous scar have same values on the development of PIH 
and the P value is not significant. 
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ECLAMPSIA * PIH 
Crosstab 
   PIH  
   0 1 2 Total 
Eclampsia N Count 134 45 20 199 
% within 
ECLAMPSIA 
67.3% 22.6% 10.1% 100.0% 
% within PIH 100.0% 100.0% 95.2% 99.5% 
% of Total 67.0% 22.5% 10.0% 99.5% 
Y Count 0 0 1 1 
% within 
ECLAMPSIA 
.0% .0% 100.0% 100.0% 
% within PIH .0% .0% 4.8% .5% 
% of Total .0% .0% .5% .5% 
 Total Count 134 45 21 200 
% within 
ECLAMPSIA 
67.0% 22.5% 10.5% 100.0% 
% within PIH 100.0% 100.0% 100.0% 100.0% 
% of Total 67.0% 22.5% 10.5% 100.0% 
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CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 8.567a 2 .014 
Likelihood Ratio 4.551 2 .103 
N of Valid Cases 200   
a. 3 cells (50.0%) have expected count less than 5. The 
minimum expected count is 11. 
Eclampsia is present with only severe PIH patients ,and 
the P value in significant 
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PAST H/O PIH  
   PIH  
   0 1 2 Total 
Past H/O 
PIH 
N Count 134 44 17 195 
% within 
PAST H/O 
PIH 
68.7% 22.6% 8.7% 100.0% 
% within PIH 100.0% 97.8% 81.0% 97.5% 
% of Total 67.0% 22.0% 8.5% 97.5% 
Y Count 0 1 4 5 
% within 
PAST H/O 
PIH 
.0% 20.0% 80.0% 100.0% 
% within PIH .0% 2.2% 19.0% 2.5% 
% of Total .0% .5% 2.0% 2.5% 
 Total Count 134 45 21 200 
% within 
PAST H/O 
PIH 
67.0% 22.5% 10.5% 100.0% 
% within PIH 100.0% 100.0% 100.0% 100.0% 
% of Total 67.0% 22.5% 10.5% 100.0% 
 91 
CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 27.041a 2 .000 
Likelihood Ratio 16.721 2 .000 
N of Valid Cases 200   
a. 3 cells (50.0%) have expected count less than 5. The 
minimum expected count is 53. 
Patients with previous history of PIH have significant 
correlation, So patients with past history of PIH have more 
chance for development of PIH in the future pregnancy.  
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Correlation of Diastolic Blood Pressure with Serum BHCG 
Variable Y BP DIASTOLIC 
Variable X SR.BHCG 
 
 
 
   
Sample size 200 
Correlation coefficient r 0.7891 
Significance level P<0.0001 
95% Confidence interval for r 0.7303 to 0.8363 
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When the diastolic blood pressure is correlated with 
serum beta HCG,there is a significant p value is present.  
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Correlation of Systolic Blood Pressure with Serum Beta 
HCG 
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 95 
Correlation 
Variable Y BP SYSTOLIC 
Variable X SR.BHCG 
 
   
Sample size 200 
Correlation coefficient r 0.7462 
Significance level P<0.0001 
95% Confidence interval for r 0.6776 to 0.8019 
When the systolic BP is correlated with the maternal 
serum beta HCG,significant correlation is present in between 
them.   
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DISCUSSION 
The  primary objective of this study was to predict the 
pregnancy induced hypertension and its severity by elevated 
serum beta HCG levels in early second trimester of pregnancy 
gestational age between 13 and 20weeks.There were many 
predictors of PIH described but none of them known to be 
with more sensitivity and specificity.  
A similar study was conducted in obstetrics and 
gynaecology department of SMS medical college, Jaipur 
which showed the association of serum beta HCG levels with 
PIH and its severity. In this study Out of 200 patients  141 
patients were primigravida,of which 97 patients(68.8%) had 
no PIH,29 patients (20.8%)had mild PIH ,15 patients (10.6%) 
had severe PIH. 48 patients were G2 of which 32 patients 
(66.7%)had no PIH ,11patients (22.9%)had mild PIH and 5 
patients(10.4%)had severe PIH.10 patients were G3 of which 
5 patients (50%) had no PIH ,4 patients (40%.) had mild PIH 
and 1 patient(10%) had severe PIH.  
In the Jaipur study ,Out of 178 patients studied ,94 
patients were primiparous (52.80%),women with PIH was 
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16(17.02%),without PIH was 78(82.98%) ,84 patients were 
multiparous(47.20%),women with PIH was 6(7.14%) and 
without PIH  was 78(92.86%).Hence , parity with association 
of PIH has no significance with the occurrence of PIH ,Hence  
parity  association with PIH is insignificant. 
For the Serum beta HCG levels in correlation  with PIH, 
Jaipur study showed out of 13 patients who developed severe 
PIH, 12 patients had beta HCG values more than 80,000miu/ml 
which had chi square value of 7.167 and p value <0.01. 
In this study out of 200 patients 66 patients were with 
PIH and 134 patients were without PIH which had a 
sensitivity of 68.2% and specificity of 96.3% and p value 
significant <0.0001.And out of 155 patients,  comparison of 
134 patients without  PIH and  21 patients with PIH had a 
sensitivity of 100% and specificity of 98.5% and p value < 
0.0001. In Correlation of  diastolic blood pressure of all 200 
patients with their diastolic blood pressure  have a significant 
correlation 0.7891 and  p value of < 0.000. 
Out of 200 patients studied the correlation of diastolic 
blood pressure with serum beta HCG levels showed a 
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correlation of 0.7462 and p value of <0.0001 which is 
statistically very significant .Out of 200 patients studied,134 
patients with no PIH had mean beta HCG levels of 71205 
mIU/ml ,45 patients with mild PIH  had beta HCG level of 
101178 mIU/ml,and 21 patients with severe PIH had mean 
beta HCG levels of 1,54, 560 mIU/ml.Thus patients without 
PIH had beta HCG levels <80,000 mIU/ml. Both patients with 
mild PIH and severe PIH had beta HCG  values 
>1,00,000mIU/ml.Particularly  21 patients with severe PIH 
had mean beta HCG values of 1,54,560 mIU/ml.  
In general recurrent risk of preeclmpsia
43
 in a women 
whose previous pregnancy was complicated by preeclampsia 
near term is approximately 10%.If a woman has previously 
suffered from severe preeclampsia,she has 20%  risk of 
developing preeclampsia. If a woman had HELLP syndrome 
or eclampsia, the risk of recurrence is 2%. 
The earlier the disease manifesting the levels of serum 
beta HCG levels was higher in patients with preeclampsia than 
in normotensive women.Wheras preeclampsia is a syndrome 
with multisystem involvement
44
, so the ideal predictive test for 
it should utilise a combination of many prediction. 
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The identification of reliable parameter indicates is a 
clinically relevant issue that could result in early therapeutic 
intervention and the better maternal and fetal outcome.  
Although there is no proven effective method for 
prevention of preeclampsia,identification of affected 
pregnancies in first trimester opens up a live window, that is 
potentially very valuable and can ultimately lead to improved 
pregnancy outcome. Identification at the end of first trimester 
allows increased surveillance
42
 of high risk pregnancies, earlier 
diagnosis of the clinical signs of disease, earlier identification 
of associated IUGR, wider ranging intervention possibilities.  
By identifying pregnant women at risk for preeclampsia 
and starting them on low dose Aspirin before 16 weeks of 
gestation, physician can reduce half the risk of preeclampsia, 
pre term birth and IUGR. For the better prediction of early 
onset preeclampsia, detection is possible only    
Hence elevated beta HCG level >1,00,000 mIU/ml 
associated with pregnancy induced hypertension and the 
severe PIH is associated with elevated beta HCG values 
>1,54,560 mIU/ml. 
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CONCLUSION 
1) The present study shows elevated maternal serum 
BETA HCG levels in early second trimester was 
associated with development of pregnancy induced 
hypertension later in the pregnancy. 
2) Elevated levels of serum BETA HCG values more than 
1,00,000 m IU/ml was associated with increased 
severity of PIH with significant p value.  
3) Other parameters like age of the patient, parity, 
gestational age, BMI of the patient which was included 
in the study did not correlate with both with 
development of PIH and its severity. 
4) Compared with other biochemical parameters which 
was used in the prediction of PIH, serum Beta HCG 
levels is associated with more sensitivity and 
specificity.  
5) Still, it needs further large randomised trials to validate 
the serum Beta HCG levels as better predictor of 
pregnancy induced hypertension and its severity.  
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PROFORMA 
INTRODUCTION 
Name of patient 
Age of patient  
Occupation 
Obstetric score 
Socio economic status- 
Gestational .age 
LMP: & EDD 
Booked & immunized 
PRESENTING COMPLAINTS; 
H/O: fever 
H/O bleeding per vaginum 
 MENSTRUAL HISTORY 
Regular cycles 
Reliability of LM.P 
MARITALHISTIORY 
Obstetric history 
Previous mode of-deliveries 
Booked 
Immunized 
Last child birth 
Previous live child 
Miscarriages 
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Bad obstetric history 
H/O GDM, gestational hypertension in previous pregnancies 
H/O recurrent urinary tract infection 
H/O anemia 
PAST HISTORY 
H/O chronic illnesses 
H/O- HT&DM 
H/O hypothyroidism 
H/O Surgeries 
GENERAL EXAMINATION 
Height 
Weight 
BMI 
Pallor 
Pedal edema 
Hydration 
VITALS 
Temperature 
Pulse rate 
Respiratory rate 
Blood pressure 
SYSTEM EXAMINATION 
CVS 
RS  
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ABDOMINAL EXAMINATION 
Fundal height 
INVESTIGATIONS 
Urine analysis 
Blood- grouping 
CBC 
High vaginal swab 
Sr.Beta HCG 
 
ULTRA SOUND 
Gestational age 
viability 
 
MONITORING 
INTERVENTION 
OUTCOME MEASURES 
 
S. No NAME AGE PARITY GEST.AGE(WKS) PRE.LSCS PAST H/O PIH BMI BP SYSTOLIC BP DIASTOLIC SR.BHCG PROTENURIA PIH ECLAMPSIA
1 HARIPRIYA 25 1 16 N N 21.99 120 70 36092 0 0 N
2 KANNAMMAL 24 1 16 N N 20.92 116 70 36980 0 0 N
3 PREMA 26 1 15 N N 24.89 110 80 45096 0 0 N
4 BINDU 23 2 17 N N 30.79 120 70 50108 0 0 N
5 PONMALAR 26 2 17 N N 28.99 132 80 51906 0 1 N
6 PRIYA 28 1 13 N N 30.4 120 76 52606 0 0 N
7 MANGAI 26 1 17 N N 19.09 120 70 52608 0 0 N
8 SARASWATHI 26 1 16 N N 24.65 124 74 52806 0 1 N
9 KAVITHA 29 2 18 N N 24.78 110 74 52908 0 0 N
10 SENTHAMARAI 24 1 16 N N 31.63 128 84 54108 0 1 N
11 FLORET 24 3 17 Y N 24.98 110 74 54808 0 0 N
12 PONNAMMAL 26 2 18 N N 31.09 110 70 55606 0 0 N
13 MAHESWARI 29 3 19 Y N 23.9 124 74 56102 0 1 N
14 VENNILA 19 1 14 N N 19 124 74 56124 0 1 N
15 KARUNYA 23 1 15 N N 22.79 120 70 56708 0 0 N
16 AYUSHA 26 1 17 N N 27.98 110 74 56786 0 0 N
17 MARAGATHAM 28 1 15 N N 30.71 126 80 56806 0 1 N
18 SASIKALA 30 2 18 N N 27.82 130 72 56980 0 1 N
19 SRIDEVI 24 1 16 N N 30.65 116 72 57302 0 0 N
20 ARUNA 22 1 15 N N 24.77 110 70 57506 0 0 N
21 INDUJA 27 1 13 N N 23.76 110 70 57704 0 0 N
22 LOGESWARI 26 1 17 N N 27.99 110 80 58404 0 0 N
23 VASANTHA 26 1 16 N N 19.87 120 70 58404 0 0 N
24 RUBINI 26 1 16 N N 24.76 120 70 58604 0 0 N
25 KAVYA 26 1 17 N N 19.8 120 74 58604 0 0 N
26 MARYAMMAL 28 1 16 N N 23.09 110 70 58804 0 0 N
27 SARANYA 28 1 15 N N 26.88 110 84 58805 0 0 N
28 DEVAKI 29 2 17 N N 18.98 116 74 58904 0 0 N
29 ANUSHA 28 1 15 N N 26.59 120 70 58906 0 0 N
30 SAVITHRI 23 1 13 N N 22.09 110 80 59702 0 0 N
31 AROKIYAMARY 25 1 17 N N 29.06 120 70 59802 0 0 N
32 SARANYA 27 1 16 N N 19.89 116 74 59906 0 0 N
MASTER CHART
S. No NAME AGE PARITY GEST.AGE(WKS) PRE.LSCS PAST H/O PIH BMI BP SYSTOLIC BP DIASTOLIC SR.BHCG PROTENURIA PIH ECLAMPSIA
33 BAGYAM 24 1 13 N N 19.85 110 80 61806 0 0 N
34 PAVAI 25 1 13 N N 25.05 120 70 61806 0 0 N
35 SUMATHI 22 1 13 N N 24.87 110 76 61906 0 0 N
36 ROJA 26 1 14 N N 24.59 120 74 61908 0 0 N
37 BABYAMMAL 25 1 17 N N 26.98 114 74 62404 0 0 N
38 VANITHA 25 1 17 N N 28.62 110 70 62508 0 0 N
39 GANGA 23 1 14 N N 28.99 116 70 62606 0 0 N
40 JOSPIN 27 2 19 Y N 22.67 120 76 63504 0 0 N
41 DEVI 30 2 15 N N 24.9 120 70 64362 0 0 N
42 SAROJA 24 1 18 N N 26.99 120 70 64506 0 0 N
43 KALAI 23 2 18 N N 29.59 120 72 64567 0 0 N
44 SEETHA 22 2 16 N N 19.8 128 70 64623 0 1 N
45 GOVINDAMMAL 26 2 15 N N 26.87 116 78 64706 0 0 N
46 MONISHA 24 1 16 N N 23.75 110 70 64806 0 0 N
47 VARALAKSHMI 24 2 15 N N 24.87 120 70 64806 0 0 N
48 SHOPIA 26 1 14 N N 24.97 110 70 64906 0 0 N
49 KARUNYA 24 1 14 N N 30.83 110 70 65906 0 0 N
50 SRIDEVI 23 1 17 N N 23.6 120 76 66123 0 0 N
51 SEETHALAKSHMI 25 1 18 N N 21.89 114 70 66808 0 0 N
52 KAVITHA 24 1 17 N N 22.55 120 70 67097 0 0 N
53 BANUMATHI 26 1 14 N N 27.66 120 70 67508 0 0 N
54 SIVASAKTHI 25 2 13 N N 27.98 116 70 67704 0 0 N
55 HEMA 22 1 15 N N 22.09 120 70 67706 0 0 N
56 SOWMYA 24 3 13 Y N 24.87 130 80 67802 0 1 N
57 KANNATHAL 22 1 14 N N 26.9 120 74 67806 0 0 N
58 KANTHA 23 1 17 N N 26.04 110 74 67808 0 0 N
59 VASANTHI 28 2 13 Y N 21.87 120 70 67895 0 0 N
60 CHELLAMMAL 27 1 14 N N 26.96 110 80 67902 0 0 N
61 CHANDRA 24 1 17 N N 22.51 120 70 67908 0 0 N
62 GOVINDAMMAL 26 1 15 N N 20.67 110 74 68408 0 0 N
63 SELVI 29 1 13 N N 26.97 110 80 68504 0 0 N
64 BABY 23 1 16 N N 25.78 110 74 68508 0 0 N
65 PAPATHI 26 2 17 N N 21.99 110 74 68702 0 0 N
66 PRIYA 25 1 15 N N 22.87 110 72 68802 0 0 N
S. No NAME AGE PARITY GEST.AGE(WKS) PRE.LSCS PAST H/O PIH BMI BP SYSTOLIC BP DIASTOLIC SR.BHCG PROTENURIA PIH ECLAMPSIA
67 VERAMMAL 23 1 14 N N 24.9 110 70 68804 0 0 N
68 MONISHA 26 1 16 N N 26.87 120 70 68806 0 0 N
69 MANGAI 23 2 16 N N 31.87 120 74 68902 0 0 N
70 YOGALAKSHMI 24 1 17 Y N 19.88 120 80 68902 0 0 N
71 KANNATHAL 23 1 16 N N 23.78 124 70 68902 0 1 N
72 HARINI 29 1 15 N N 27.9 116 70 68904 0 0 N
73 KANTHA 28 1 16 N N 25.8 120 70 69406 0 0 N
74 NITHYA 29 2 13 Y N 28.7 110 74 69807 0 0 N
75 STELLAMARY 28 1 16 N N 21.77 120 70 70608 0 0 N
76 SINDU 26 1 14 N N 21.85 120 70 71704 0 0 N
77 MALA 21 1 14 N N 22.8 126 74 71924 0 1 N
78 RAJESHWARI 22 2 16 N N 19.7 116 74 72106 0 0 N
79 GEETHA 27 1 18 N N 19.32 110 80 72404 0 0 N
80 MANJULA 27 2 16 N N 23.4 120 70 72410 0 0 N
81 MARY 28 1 15 N N 24.78 120 70 72503 0 0 N
82 KANIMOZHI 28 2 18 N N 30.88 116 70 72508 0 0 N
83 GIRIJA 24 1 16 N N 26.09 116 70 72606 0 0 N
84 AMUTHA 27 1 16 N N 19.44 120 78 72606 0 0 N
85 GAJALAKSHMI 26 3 14 Y N 27.34 110 76 72608 0 0 N
86 PREMA 29 1 15 N N 23.77 120 70 72608 0 0 N
87 JEYANTHI 28 1 14 N N 23.93 110 70 72802 0 0 N
88 KANTHA 24 1 17 N N 25.09 110 74 72804 0 0 N
89 GOVINDAMMAL 28 2 17 N N 26.56 110 70 72806 0 0 N
90 KANTHA 24 1 16 N N 21.77 110 70 72904 0 0 N
91 ANUSHA 25 1 16 N N 29.78 110 70 73306 0 0 N
92 RAJATHI 23 1 18 N N 26.99 110 70 73806 0 0 N
93 RESHMI 23 2 14 N N 28.62 118 70 74204 0 0 N
94 SINDHU 29 1 17 N N 28.7 110 70 74403 0 0 N
95 VETRISELVI 23 1 13 N N 26.84 110 80 74602 0 0 N
96 ANANTHI 24 1 16 N N 23.89 110 72 74804 0 0 N
97 KASTHURI 28 1 18 N N 28.99 120 70 74806 0 0 N
98 KALAISELVI 26 2 16 Y N 29.64 124 78 74806 0 1 N
99 SUMATHI 26 1 15 N N 21.09 116 70 74902 0 0 N
100 ROJA 27 1 16 N N 19.5 110 80 75506 0 0 N
S. No NAME AGE PARITY GEST.AGE(WKS) PRE.LSCS PAST H/O PIH BMI BP SYSTOLIC BP DIASTOLIC SR.BHCG PROTENURIA PIH ECLAMPSIA
101 PONMALAR 23 1 18 N N 31.55 120 80 75604 0 0 N
102 GAYATHRI 26 1 14 N N 26.99 120 70 75706 0 0 N
103 MUNEERA 24 3 15 N N 24.66 110 70 76000 0 0 N
104 INDUJA 26 2 19 Y N 29.7 114 76 76000 0 0 N
105 AMMU 19 1 16 N N 27 130 70 76101 0 1 N
106 INDUMATHI 26 1 14 N N 24.66 120 70 76404 0 0 N
107 STELLA 27 2 16 N N 18.77 110 80 76508 0 0 N
108 KANNAKINAGHY 24 1 18 N N 26.54 120 80 76802 0 0 N
109 SARANYA 26 1 18 N N 22.09 110 74 76804 0 0 N
110 NITHYAGANESAN 27 1 19 N N 20.56 110 80 77404 0 0 N
111 RENUKADEVI 21 1 18 N N 26.8 130 70 78107 0 1 N
112 VANISHREE 22 1 16 N N 19.9 130 74 78124 0 1 N
113 DEEPIKA 24 1 17 N N 22.87 110 70 78302 0 0 N
114 ARULAMMAL 29 1 18 N N 28.97 110 80 78502 0 0 N
115 SAROJA 25 1 17 N N 29.65 116 70 78506 0 0 N
116 DEVI 26 2 16 N N 25.98 120 70 78802 0 0 N
117 ELLAMMAL 27 1 15 N N 23.79 120 70 78804 0 0 N
118 NIRUBAMA 28 2 17 N N 21.87 120 74 78804 0 0 N
119 ROSEMARY 23 1 16 N N 21.58 120 74 78804 0 0 N
120 PONVASUKI 24 2 14 N N 23.11 130 78 78804 0 1 N
121 SNEHA 26 1 18 N N 28.09 110 80 78806 0 0 N
122 PARASAKTHI 26 1 14 N N 23.98 116 70 78806 0 0 N
123 DEVI 22 1 18 N N 24.87 120 74 78806 0 0 N
124 SAKTHIPRIYA 25 1 15 N N 23.01 120 80 78806 0 0 N
125 MAHESWARI 24 2 16 N N 29.31 110 70 78905 0 0 N
126 ANUSIYA 29 1 14 N N 24.83 110 80 78906 0 0 N
127 NANTHINI 26 1 13 N N 24.79 116 70 78906 0 0 N
128 AMUTHA 28 1 15 N N 20.66 120 70 78965 0 0 N
129 NITHYA 25 1 13 N N 21.99 128 70 79102 0 1 N
130 CHRISTINA 24 1 14 N N 23.8 120 70 79124 0 0 N
131 DEEPTHI 26 1 16 N N 29.04 110 70 79508 0 0 N
132 SUGANTHA 28 1 15 N N 30.98 110 76 79902 0 0 N
133 SAGUNTHALA 28 2 15 Y N 31.9 116 70 80508 0 0 N
134 PONNAMMAL 23 1 14 N N 30.78 120 80 80608 0 0 N
S. No NAME AGE PARITY GEST.AGE(WKS) PRE.LSCS PAST H/O PIH BMI BP SYSTOLIC BP DIASTOLIC SR.BHCG PROTENURIA PIH ECLAMPSIA
135 MALAR 29 3 13 N N 24.09 130 70 80987 0 1 N
136 VINITHA 20 1 16 N N 30.2 130 70 81806 0 1 N
137 SUGANTHA 26 2 14 N N 32.09 110 70 82604 0 0 N
138 GOVINDAMMAL 24 1 16 N N 27.99 110 70 82608 0 0 N
139 SUMATHY 31 3 17 Y N 21.5 120 70 84506 0 0 N
140 MALLIKA 26 1 18 N N 19.76 110 76 84602 0 0 N
141 PARVATHY 21 2 19 N N 22.6 110 70 84827 0 0 N
142 KANNAMAL 30 3 15 Y N 22.8 120 70 85403 0 0 N
143 SUNITHA 27 2 17 N N 22.8 110 84 85503 0 0 N
144 PRAVITHA 21 1 15 N N 21.7 126 74 86124 0 1 N
145 BAGYAM 24 1 15 N N 20.32 130 70 86704 0 1 N
146 ANNAMMAL 26 1 17 N N 29.77 110 80 86804 0 0 N
147 SUNITHA 27 1 15 N N 29.07 120 70 88000 0 0 N
148 MALLI 22 2 13 N N 24 116 74 88806 0 0 N
149 HEMA 24 1 14 N N 21.08 110 70 89904 0 0 N
150 KAVITHA 23 1 13 N N 21.98 116 70 89904 0 0 N
151 BHARATHI 22 1 16 N N 21.5 128 74 90961 0 1 N
152 JOTHI 27 2 18 Y N 29.04 116 74 92606 0 0 N
153 MARY 23 1 15 N N 28.9 110 74 95904 0 0 N
154 RANI 22 2 13 Y N 24.7 128 70 96107 0 1 N
155 MALLIGA 21 1 15 N N 24.9 128 74 96162 0 1 N
156 RATHIDEVI 19 1 14 N N 26.9 128 70 96427 0 1 N
157 KANNATHAL 25 1 16 N N 21.99 130 86 96708 0 1 N
158 SRIDEVI 25 1 16 N N 31..09 110 70 96786 0 0 N
159 HEMAMALINI 29 2 16 Y Y 26.99 140 96 96999 1 2 N
160 KANATHA 29 2 17 Y N 21.6 114 70 98750 0 0 N
161 PANIMALAR 27 1 15 N N 27.66 136 84 99609 0 1 N
162 RAJI 24 1 15 N N 28.9 140 90 100124 0 2 N
163 VALLIARASI 22 1 14 N N 24.83 140 82 100567 0 1 N
164 GOVINDAMMAL 26 1 13 N N 23.19 130 80 104608 0 1 N
165 KAVITHA 26 1 14 N N 23.45 136 90 110307 1 1 N
166 MUTHAMMA 31 1 18 N N 23.75 136 90 110450 0 1 N
167 SONIA 29 4 15 Y Y 26..98 130 84 112306 0 1 N
168 MONISHA 30 1 16 N N 24.87 126 90 115308 0 1 N
S. No NAME AGE PARITY GEST.AGE(WKS) PRE.LSCS PAST H/O PIH BMI BP SYSTOLIC BP DIASTOLIC SR.BHCG PROTENURIA PIH ECLAMPSIA
169 RAMYA 21 1 16 N N 21.8 140 90 121006 1 2 N
170 VAISNAVI 22 1 14 N N 27.8 136 96 125508 0 1 N
171 FATHIMA 26 1 15 N N 26.88 140 90 132000 1 2 N
172 SARITHA 28 3 16 N N 22.09 130 86 132987 0 1 N
173 SUMANGALI 24 1 14 N N 24..98 140 90 134508 0 2 N
174 MANJULA 19 2 15 N N 26.7 140 90 135906 0 2 N
175 vaisnavi 28 2 17 N N 26.98 120 74 142000 0 0 N
176 VANITHA 25 2 14 Y N 29.71 150 90 142604 0 2 N
177 GEETHA 22 1 12 N N 31.99 130 96 144802 0 1 N
178 VANITHA 32 1 14 N N 29.9 140 100 145762 2 2 N
179 KANNAKI 26 2 16 Y N 30.54 140 80 154378 1 1 N
180 ABI 29 2 14 Y N 25.9 140 88 154606 1 1 N
181 REVATHY 25 1 15 N N 24.09 130 100 154734 0 2 N
182 SHALINI 26 1 14 N N 30.45 126 90 154906 0 1 N
183 SEETHA 24 1 18 N N 26.88 126 98 156406 0 1 N
184 DEEPTHI 26 1 14 N N 21.78 140 90 156704 1 2 N
185 ARUNA 22 1 14 N N 21.56 130 98 156706 1 1 N
186 BARANI 28 2 15 N N 31.67 130 98 156804 1 1 N
187 VIMALA 29 2 13 Y Y 20.76 150 86 165000 2 2 N
188 SHEEPA 27 2 16 N N 21.93 136 96 165345 2 1 N
189 MAHESWARI 20 1 15 N N 29.9 150 100 174230 1 2 N
190 DEVAKI 26 3 18 Y N 25.75 150 86 175302 1 2 N
191 GOWRI 28 2 16 N N 19.59 150 96 175602 1 2 N
192 VIJI 22 1 17 N N 23.9 130 80 176102 0 1 N
193 SANTHAYI 27 1 16 N N 28.09 150 90 176987 1 2 N
194 DHANAM 26 1 16 N N 29.7 150 96 178760 1 2 N
195 SELVI 24 1 16 N Y 21.43 140 90 178908 2 2 N
196 SUMATHI 24 1 19 N N 21.87 150 100 196768 2 2 N
197 TAMILSELVI 25 1 14 N Y 32.85 160 110 197650 1 2 Y
198 SENTHAMIL 23 1 15 N N 27.09 150 90 149802 0 2 N
199 NAGESHWARI 28 2 13 N N 22.8 130 96 186214 1 1 N
200 MURUGAMMAL 25 1 14 N N 23.5 146 100 156405 1 2 N
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